Prestige Consumer Healthcare (NYSE:PBH) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a research note issued to investors on Saturday.

Several other research firms have also commented on PBH. Royal Bank of Canada raised Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. DA Davidson increased their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. Oppenheimer raised their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Finally, Canaccord Genuity Group upped their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $93.33.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $89.24 on Friday. The business’s 50-day moving average is $83.25 and its two-hundred day moving average is $81.88. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The firm has a market capitalization of $4.41 billion, a P/E ratio of 20.90, a P/E/G ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare has a 1 year low of $62.35 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The firm had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. During the same period in the prior year, the firm earned $1.02 earnings per share. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. Analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at $1,544,130. The trade was a 8.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.60% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently bought and sold shares of the business. Kestra Investment Management LLC purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $27,000. CIBC Private Wealth Group LLC raised its stake in Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after acquiring an additional 152 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare during the 1st quarter worth approximately $38,000. Headlands Technologies LLC acquired a new stake in Prestige Consumer Healthcare during the 4th quarter worth approximately $40,000. Finally, McIlrath & Eck LLC grew its stake in shares of Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after purchasing an additional 154 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.